Ischemia modified albumin changes - Review and clinical implications

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 2, 2011, Pages 177-184

  Sbarouni, Eftihia ^a   Georgiadou, Panagiota ^a   Voudris, Vassilis ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

biomarkers; ischemia; ischemia modified albumin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; COPPER; IRON; ISCHEMIA MODIFIED ALBUMIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; SERUM ALBUMIN; SUPEROXIDE; TROPONIN;

ACIDOSIS; ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTERY OCCLUSION; ATHEROSCLEROTIC PLAQUE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOVERSION; CHOLESTEROL BLOOD LEVEL; COLORIMETRY; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DELIVERY; ELECTROCARDIOGRAM; EMERGENCY WARD; ENDOMETRIOSIS; EXERCISE; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPOXIA; INFECTION; ISCHEMIA; KIDNEY FAILURE; LIVER CIRRHOSIS; LUNG EMBOLISM; MEDLINE; MEMBRANE DAMAGE; NEOPLASM; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; REPERFUSION INJURY; RESUSCITATION; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SUBARACHNOID HEMORRHAGE; SYSTEMIC SCLEROSIS; THORAX PAIN;

BIOLOGICAL MARKERS; COLORIMETRY; HUMANS; ISCHEMIA; PROGNOSIS; SERUM ALBUMIN;

EID: 79952081239     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.037     Document Type: Review

References (81)

1. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, et al, Committee on Standardization of Markers of Cardiac Damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51:810-24.
2. Collinson PO, Gaze DC. Biomarkers of cardiovascular damage and dysfunction - an overview. Heart Lung Circ 2007;16: S71-82.
3. Bar-Or D, Lau E, Winkler JV. Novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia - a preliminary report. J Emerg Med 2000;19:311-5.
4. Chan B, Dodsworth N, Woodrow J, Tucker A, Harris R. Site-specific N-terminal auto-degradation of human serum albumin. Eur J Biochem 1995;227:524-8.
5. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2q) and Ni(2q) binding amino-acid residues of the N-terminus of human albumin. Eur J Biochem 2001;268:42-7.
6. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006; 92:113-4. (Pubitemid 43021873)
7. Erturk E, Cekic B, Geze S, Kosucu M, Coskun I, Eroglu A, et al. Comparison of the effect of propofol and N-acetyl cysteine in preventing ischaemia-reperfusion injury. Eur J Anaesthesiol 2009;26:279-84.
8. Turedi S, Gunduz A, Mentese A, Dasdibi B, Karahan SC, Sahin A, et al. Investigation of the possibility of using ischemia-modified albumin as a novel and early prognostic marker in cardiac arrest patients after cardiopulmonary resuscitation. Resuscitation 2009;80:994-9.
9. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Samimi-Fard S, Reiter RJ, Kaski JC. Association of ischemia-modified albumin and melatonin in patients with ST-elevation myocardial infarction. Atherosclerosis 2008;199:73-8. (Pubitemid 351842702)
10. van Rijn BB, Franx A, Sikkema JM, van Rijn HJ, Bruinse HW, Voorbij HA. Ischemia modified albumin in normal pregnancy and preeclampsia. Hypertens Pregnancy 2008;27:159-67. (Pubitemid 351892682)
11. Seneş M, Kazan N, Coşkun O, Zengi O, Inan L, Yücel D. Oxidative and nitrosative stress in acute ischaemic stroke. Ann Clin Biochem 2007;44:43-7. (Pubitemid 46168800)
12. Borderie D, Allanore Y, Meune C, Devaux JY, Ekindjian OG, Kahan A. High ischemia-modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. Clin Chem 2004;50:2190-3. (Pubitemid 39425871)
13. Montagnana M, Lippi G, Volpe A, Salvagno GL, Biasi D, Caramaschi P, et al. Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 2006;39:913-7. (Pubitemid 44363080)
14. Abboud H, Labreuche J, Meseguer E, Lavallee PC, Simon O, Olivot JM, et al. Ischemia-modified albumin in acute stroke. Cerebrovasc Dis 2007;23:216-20. (Pubitemid 46239165)
15. Gunduz A, Turkmen S, Turedi S, Mentese A, Yulug E, Ulusoy H, et al. Time-dependent variations in ischemia-modified albumin levels in mesenteric ischemia. Acad Emerg Med 2009;16: 539-43.
16. Hacker M, Hoyer HX, la Fougère C, Akcakoyunlu E, Schuhmann C, Förster S, et al. Effects of peripheral vascular intervention on ischemia-modified albumin. Coronary Artery Dis 2007;18:375-9.
17. Mentese A, Mentese U, Turedi S, Gunduz A, Karahan SC, Topbas M, et al. Effect of deep vein thrombosis on ischaemia-modified albumin levels. Emerg Med J 2008;25:811-4.
18. Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, et al. Evaluation of ischaemia-modified albumin as a marker of myocardial ischaemia in end-stage renal disease. Clin Sci (Lond) 2007;113:25-32. (Pubitemid 47066022)
19. Aslan D, Apple FS. Ischemia modified albumin: clinical and analytical update. Lab Med 2004;35:1-5.
20. Wu AH, Morris DL, Fletcher DR, Apple FS, Christenson RH, Painter PC. Analysis of the albumin cobalt binding (ACB) test as an adjunct to cardiac troponin I for the early detection of acute myocardial infarction. Cardiovasc Toxicol 2001;1: 147-51.
21. Gidenne S, Ceppa F, Fontan E, Perrier F, Burnat P. Analytical performance of the albumin cobalt binding (ACB) test on the Cobas MIRA Plus analyzer. Clin Chem Lab Med 2004;42: 455-61. (Pubitemid 38585191)
22. Beetham R, Monk C, Keating L, Benger JR, Kendall J. Effects of storage at -20 degrees C on ischaemia-modified albumin results. Ann Clin Biochem 2006;43:500-2. (Pubitemid 44808276)
23. Govender R, De Greef J, Delport R, Becker PJ, Vermaak WJ. Biological variation of ischaemia-modified albumin in healthy subjects. Cardiovasc J Afr 2008;19:141-4.
24. Bhagavan NV, Ha JS, Park JH, Honda SA, Rios CN, Sugiyama C, et al. Utility of serum fatty acid concentrations as a marker for acute myocardial infarction and their potential role in the formation of ischemia-modified albumin: a pilot study. Clin Chem 2009;55:1588-90.
25. Mothes E, Faller P. Evidence that the principal CoII-binding site in human serum albumin is not at the N-terminus: implication on the albumin cobalt binding test for detecting myocardial ischemia. Biochemistry 2007;46:2267-74. (Pubitemid 46355336)
26. Bar-Or D, Rael LT, Bar-Or R, Slone DS, Mains CW, Rao NK, et al. The cobalt-albumin binding assay: insights into its mode of action. Clin Chim Acta 2008;387:120-7. (Pubitemid 350050944)
27. Bhagavan NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003;49:581-5. (Pubitemid 36379523)
28. Bar-Or D, Winkler JV, Vanbenthuysen K, Harris L, Lau E, Hetzel FW. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am Heart J 2001;141: 985-91.
29. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003;107:2403-5. (Pubitemid 36605219)
30. Hjortshøj S, Dethlefsen C, Kristensen SR, Ravkilde J. Kinetics of ischaemia modified albumin during ongoing severe myocardial ischaemia. Clin Chim Acta 2009;403:114-20.
31. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischemia-modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med 2007;45:261-2. (Pubitemid 46294690)
32. Zapico-Muñiz E, Santaló-Bel M, Mercé-Muntañola J, Montiel JA, Martínez-Rubio A, Ordóñez-Llanos J. Ischemia-modified albumin during skeletal muscle ischemia. Clin Chem 2004;50: 1063-5. (Pubitemid 38725798)
33. Maguire OC, Cunninngham SK. Ischaemia-modified albumin: fact or fiction? Ann Clin Biochem 2010;47:182-3.
34. Gaze DC, Crompton L, Collinson P. Ischemia modified albumin concentrations should be interpreted with caution in patients with low serum albumin concentrations. Med Princ Pract 2006;15:322-4. (Pubitemid 43876749)
35. Hakligör A, Kösem A, Seneş M, Yücel D. Effect of albumin concentration and serum matrix on ischemia-modified albumin. Clin Biochem 2010;43:345-8.
36. Lee YW, Kim HJ, Cho YH, Shin HB, Choi TY, Lee YK. Application of albumin-adjusted ischemia modified albumin index as an early screening marker for acute coronary syndrome. Clin Chim Acta 2007;384:24-7. (Pubitemid 47247405)
37. Collinson PO, Gaze DC. Ischaemia-modified albumin: clinical utility and pitfalls in measurement. J Clin Pathol 2008;61: 1025-8.
38. Garrido IP, Roy D, Calvino R, Vazquez-Rodriguez JM, Aldama G, Cosin-Sales J, et al. Comparison of ischemia-modified albumin levels in patients undergoing percutaneous coronary intervention for unstable angina pectoris with versus without collaterals. Am J Cardiol 2004;93:88-90. (Pubitemid 38022041)
39. Quiles J, Roy D, Gaze D, Garrido IP, Avanzas P, Sinha M, et al. Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol 2003; 92:322-4. (Pubitemid 36897723)
40. Dominguez-Rodriguez A, Kaski JC, Abreu-Gonzalez P, Samimi-Fard S. Role of ischemia modified albumin to ST-segment resolution after mechanical reperfusion in patients with ST-segment elevation myocardial infarction. Atherosclerosis 2009; 203:576-80.
41. Sinha MK, Vazquez JM, Calvino R, Gaze DC, Collinson PO, Kaski JC. Effects of balloon occlusion during percutaneous coronary intervention on circulating ischemia modified albumin and transmyocardial lactate extraction. Heart 2006;92:1852-3. (Pubitemid 44851340)
42. Cho DK, Choi JO, Kim SH, Choi J, Rhee I, Ki CS, et al. Ischemia-modified albumin is a highly sensitive serum marker of transient myocardial ischemia induced by coronary vasospasm. Coronary Artery Dis 2007;18:83-7.
43. Antman EM, Grudzien C, Sacks DB. Evaluation of a rapid bedside assay for detection of serum cardiac troponin T. J Am Med Assoc 1995;273:1279-82.
44. Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, et al. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicentric study. Clin Chem 2001;47:464-70. (Pubitemid 32222460)
45. Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC. Role of ischemia modified albumin a new biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004;21:29-34. (Pubitemid 38165479)
46. Roy D, Quiles J, Aldama G, Sinha M, Avanzas P, Arroyo-Espliguero R, et al. Ischemia modified albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol 2004;97:297-301. (Pubitemid 39286849)
47. Collinson PO, Gaze DC, Bainbridge K, Morris F, Morris B, Price A, et al. Utility of admission cardiac troponin and "Ischemia Modified Albumin" measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emerg Med J 2006;23:256-61. (Pubitemid 44295312)
48. Peacock F, Morris DL, Anwaruddin S, Christenson RH, Collinson PO, Goodacre SW, et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 2006;152:253-62. (Pubitemid 44093396)
49. Keating L, Benger JR, Beetham R, Bateman S, Veysey S, Kendall J, et al. The PRIMA study: presentation ischaemia-modified albumin in the emergency department. Emerg Med J 2006;23:764-8.
50. Anwaruddin S, Januzzi JL Jr, Baggish AL, Lewandrowski EL, Lewandrowski KB. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol 2005;123:140-5. (Pubitemid 40066181)
51. Liyan C, Jie Z, Xiaozhou H. Prognostic value of combination of heart-type fatty acid-binding protein and ischemia-modified albumin in patients with acute coronary syndromes and normal troponin T values. J Clin Lab Anal 2009;23:14-8.
52. Shave R, George K, Gaze D. The influence of exercise upon cardiac biomarkers: a practical guide for clinicians and scientists. Curr Med Chem 2007;14:1427-36. (Pubitemid 46902224)
53. Apple FS, Quist HE, Otto AP, Mathews WE, Murakami MM. Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race. Clin Chem 2002;48:1097-100. (Pubitemid 34680908)
54. Falkensammer J, Stojakovic T, Huber K, Hammerer-Lercher A, Gruber I, Scharnagl H, et al. Serum levels of ischemia-modified albumin in healthy volunteers after exercise-induced calf-muscle ischemia. Clin Chem Lab Med 2007;45:535-40. (Pubitemid 46632208)
55. Roy D, Quiles J, Sharma R, Sinha M, Avanzas P, Gaze D, et al. Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem 2004;50:1656-60. (Pubitemid 39121235)
56. Van der Zee PM, Verberne HJ, Straalen JP, Sanders GT, Van Eck-Smit BL, de Winter RJ, et al. Ischemia-modified albumin measurements in symptom-limited exercise myocardial perfusion scintigraphy reflect serum albumin concentrations but not myocardial ischemia. Clin Chem 2005;51:1744-6. (Pubitemid 41233120)
57. Sbarouni E, Georgiadou P, Theodorakis GN, Kremastinos DT. Ischemia-modified albumin in relation to exercise stress testing. J Am Coll Cardiol 2006;48:2482-4. (Pubitemid 44881211)
58. Kurz K, Voelker R, Zdunek D, Wergeland R, Hess G, Ivandic B, et al. Effect of stress-induced reversible ischemia on serum concentrations of ischemia-modified albumin, natriuretic peptides and placental growth factor. Clin Res Cardiol 2007;96: 152-9. (Pubitemid 46363763)
59. Sbarouni E, Georgiadou P, Panagiotakos D, Kyrzopoulos S, Tsiapras D, Voudris V, et al. Ischemia modified albumin in relation to pharmacologic stress testing in coronary artery disease. Clin Chim Acta 2008;396:58-61.
60. Roy D, Quiles J, Sinha M, Floros D, Gaze D, Collinson P, et al. Effect of radiofrequency catheter ablation on the biochemical marker ischemia-modified albumin. Am J Cardiol 2004; 94:234-6. (Pubitemid 38902880)
61. Sbarouni E, Georgiadou P, Panagiotakos D, Livanis EG, Theodorakis GN, Kremastinos DT. Ischaemia modified albumin in radiofrequency catheter ablation. Europace 2007;9:127-9. (Pubitemid 46237978)
62. Roy D, Quiles J, Sinha M, Aldama G, Gaze D, Kaski JC. Effect of direct-current cardioversion on ischemia-modified albumin in patients with atrial fibrillation. Am J Cardiol 2004;93:366-8. (Pubitemid 38167441)
63. Sbarouni E, Georgiadou P, Panagiotakos D, Livanis E, Theodorakis GN, Kremastinos DT. The ischemia-modified albumin in relation to pacemaker and defibrillator implantation. Pacing Clin Electrophysiol 2008;31:83-7.
64. Turedi S, Gunduz A, Mentese A, Karahan SC, Yilmaz SE, Eroglu O, et al. Value of ischemia-modified albumin in the diagnosis of pulmonary embolism. Am J Emerg Med 2007;25: 770-3. (Pubitemid 47385040)
65. Sbarouni E, Georgiadou P, Koutelou M, Sklavainas I, Panagiotakos D, Voudris V. Ischaemia-modified albumin in dilated cardiomyopathy. Ann Clin Biochem 2009;46:241-3.
66. Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus - preliminary report. Dis Markers 2008;24:311-7.
67. Duarte MM, Rocha JB, Moresco RN, Duarte T, Da Cruz IB, Loro VL, et al. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 2009;42:666-71.
68. Kazanis K, Dalamaga M, Nounopoulos C, Manolis AS, Sakellaris N, Jullien G, et al. Ischemia modified albumin, high-sensitivity C-reactive protein and natriuretic peptide in patients with coronary atherosclerosis. Clin Chim Acta 2009;408:65-9.
69. Sbarouni E, Georgiadou P, Panagiotakos D, Alivizatos PA, Voudris V. Increased ischaemia modified albumin following coronary artery bypass grafting. Biomarkers 2009;14:38-42.
70. Montagnana M, Lippi G, Regis D, Fava C, Viola G, Bartolozzi P, et al. Evaluation of cardiac involvement following major orthopedic surgery. Clin Chem Lab Med 2006;44:1340-6. (Pubitemid 44706713)
71. Refaai MA, Wright RW, Parvin CA, Gronowski AM, Scott MG, Eby CS. Ischemia-modified albumin increases after skeletal muscle ischemia during arthroscopic knee surgery. Clin Chim Acta 2006;366:264-8. (Pubitemid 43330993)
72. Aparci M, Kardesoglu E, Ozmen N, Ozcan O, Cebeci BS, Cingozbay BY, et al. Prognostic significance of ischemia-modified albumin in patients with acute coronary syndrome. Coronary Artery Dis 2007;18:367-73. (Pubitemid 47186837)
73. Consuegra-Sanchez L, Bouzas-Mosquera A, Sinha MK, Collinson PO, Gaze DC, Kaski JC. Ischemia-modified albumin predicts short-term outcome and 1-year mortality in patients attending the emergency department for acute ischemic chest pain. Heart Vessels 2008;23:174-80. (Pubitemid 351722407)
74. Manini AF, Ilgen J, Noble VE, Bamberg F, Koenig W, Bohan JS, et al. Derivation and validation of a sensitive IMA cutpoint to predict cardiac events in patients with chest pain. Emerg Med J 2009;26:791-6.
75. Worster A, Devereaux PJ, Heels-Ansdell D, Guyatt GH, Opie J, Mookadam F, et al. Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome. Can Med Assoc J 2005;172:1685-90. (Pubitemid 40896860)
76. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Samimi-Fard S, Kaski JC. Relation of ischemia-modified albumin levels and left ventricular systolic function in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Clin Chim Acta 2008;388:196-9. (Pubitemid 350266589)
77. Dominguez-Rodriguez A, Abreu-Gonzalez P, Jimenez-Sosa A, Samimi-Fard S, Idaira HB. Does ischemia-modified albumin add prognostic value to the thrombolysis in myocardial infarction risk score in patients with ST-segment elevation myocardial infarction treated with primary angioplasty? Biomarkers 2009;14:43-8.
78. Bali L, Cuisset T, Giorgi R, Monserrat C, Quilici J, Carrega L, et al. Prognostic value of ischaemia-modified albumin in patients with non-ST-segment elevation acute coronary syndromes. Arch Cardiovasc Dis 2008;101:645-51.
79. Dusek J, St'ásek J, Tichý M, Bis J, Gregor J, Vojácek J, et al. Prognostic significance of ischemia modified albumin after percutaneous coronary intervention. Clin Chim Acta 2006;367: 77-80.
80. Van Belle E, Dallongeville J, Vicaut E, Degrandsart A, Baulac C, Montalescot G, OPERA Investigators. Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. Am Heart J 2010;159:570-6.
81. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361: 858-67.